High Efficacy Halts ViiV HIV Prevention Study Early
ViiV Hopes Faster Cabotegravir Approval Will Be The Result
Prospects have improved for ViiV’s long-acting, injectable cabotegravir to be approved early for HIV prevention after a Phase III trial was stopped early due to efficacy.
You may also be interested in...
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.
Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.